[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sensory-neuronopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sensory-neuronopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641849","clinical-evaluation-of-sensory-neuronopathies-the-neuronoscore-study-100641849",false,"NCT07651540","Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study","NEURONOSCORE","Inclusion Criteria:\n\n* Patient affiliated with or beneficiary of a social security system\n* Patient having received appropriate study information\n* Adult patient ≥18 years old, male or female\n* Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria\n* SN with one of the following etiologies:\n\nParaneoplastic SN with anti-Hu or anti-CV2\u002FCRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome\n\nExclusion Criteria:\n\n* Patient unable to understand or read French\n* Patient refusal to participate\n* Patient known to have another neuropathy phenotype and\u002For etiology that could significantly influence clinical scales and electrophysiological parameters, including:\n\n  * Diabetes mellitus\n  * Significant alcohol consumption\n  * Severe chronic kidney disease (GFR \\\u003C30 ml\u002Fmin)\n  * Vitamin B12 and\u002For vitamin E deficiency\n  * Vitamin B6 excess\n  * Chemotherapy other than platinum salts\n  * HIV infection","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"NA","Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4.\n\nThe absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available \"general neuropathy\" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations.\n\nAs a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.",[26],"Sensory Neuronopathy",[28,29,30],"neurology","specific scale","rare neuropathy","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":20},"2026-06-25",{"date":39,"type":20},"2028-06-25",{"name":41,"class":42},"Centre Hospitalier Universitaire de Saint Etienne","OTHER",19,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100621054","nerve-ultrasound-in-acquired-and-genetic-sensory-neuronopathies-100621054","NCT07365631","Nerve Ultrasound in Acquired and Genetic Sensory Neuronopathies","The Role of Nerve Ultrasound in Distinguishing Acquired and Genetic Sensory Neuronopathies (Ganglionopathy): A Multicenter Retrospective Study","GANECHO","Inclusion Criteria:\n\n* Sensory ganglionopathy diagnosed according to the criteria of Camdessanché et al.\n* Nerve ultrasound performed as part of routine clinical care.\n* Age \\> 18 years.\n\nExclusion Criteria:\n\n* Comorbid conditions that may interfere with the interpretation of sensory ganglionopathy.\n* Lack of consent (patient opposition to the use of clinical data for research).",{"count":53,"type":20},50,"OBSERVATIONAL","Sensory neuronopathies (also called sensory ganglionopathies) are rare and heterogeneous disorders of genetic or acquired origin, caused by degeneration of the dorsal root ganglia. Their diagnosis currently relies on a combination of clinical evaluation and electrophysiological testing, as no specific biomarker is available.\n\nEarly diagnosis is particularly important in acquired forms, where early treatment can significantly influence prognosis.\n\nRecent studies have reported a characteristic ultrasound pattern in several genetic sensory neuronopathies, showing abnormally small-caliber peripheral nerves in the upper limbs. However, these findings have only been described in genetic conditions. It is therefore unknown whether this ultrasound pattern is specific to genetic causes or may also occur in acquired sensory neuronopathies, especially those with long-standing evolution.\n\nThis retrospective multicenter study will analyze data already collected as part of routine care in approximately 50 patients with sensory neuronopathy. The objective is to compare nerve ultrasound findings between genetic and acquired forms, and to evaluate their association with clinical severity and electrophysiological parameters. Determining whether nerve atrophy observed on ultrasound is specific to genetic etiologies could help integrate ultrasound into the diagnostic workup, guiding the choice of complementary tests such as genetic analyses or early treatment initiation in acquired cases.",[26],[58,59,60,61],"Nerve ultrasound","sensory neuronopathy","ganglionopathy","CANVAS","2026-01-19",{"date":64,"type":35},"2026-01-26",{"date":66,"type":20},"2026-01",{"date":68,"type":20},"2027-01",{"name":70,"class":42},"Assistance Publique - Hôpitaux de Paris"]